FDA lifts clinical hold on KalVista's Phase 2 KVD824 trial for HAE prophylaxis

KalVista Pharmaceuticals, Inc.

FDA removed clinical hold on Phase 2 KOMPLETE trial of KVD824 for oral prophylactic treatment of hereditary angioedema.
Clinical hold lifted after FDA review of KalVista's responses on certain preclinical studies of KVD824.
Protocol refinements made; company working to resume study activities as soon as possible.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.